ライフサイエンスコーパス: systolic dysfunction

1 rdiographic left ventricular hypertrophy and systolic dysfunction.

2 re, especially in patients with pre-existing systolic dysfunction.

3 tivessel disease and severe left ventricular systolic dysfunction.

4 in patients with CHF due to left ventricular systolic dysfunction.

5 uction of mechanical stress in patients with systolic dysfunction.

6 directly associated with the development of systolic dysfunction.

7 patients with atrioventricular block and LV systolic dysfunction.

8 neutropenia or symptomatic left ventricular systolic dysfunction.

9 on in patients with heart failure because of systolic dysfunction.

10 been predominantly confined to patients with systolic dysfunction.

11 e (ACE) inhibitors for left ventricular (LV) systolic dysfunction.

12 e is increasingly performed in patients with systolic dysfunction.

13 cardial disease with marked left ventricular systolic dysfunction.

14 monary hypertension (PH) in patients with LV systolic dysfunction.

15 hypertrophy, left chambers alterations, and systolic dysfunction.

16 results in extensive myocardial necrosis and systolic dysfunction.

17 r apical pacing may promote left ventricular systolic dysfunction.

18 r wall edema was not coupled with aggravated systolic dysfunction.

19 crease in contractility (-54%; P<0.001) with systolic dysfunction.

20 ated with revascularization in patients with systolic dysfunction.

21 dilation associated with mild nonprogressive systolic dysfunction.

22 diac [dATP] as a therapeutic option to treat systolic dysfunction.

23 gical cardiac remodelling, and diastolic and systolic dysfunction.

24 t compared with subjects with more severe LV systolic dysfunction.

25 isk of SCD in patients with left ventricular systolic dysfunction.

26 RAs on SCD in patients with left ventricular systolic dysfunction.

27 k(+/+) marrow into Mertk(-/-) mice corrected systolic dysfunction.

28 e of death in patients with left ventricular systolic dysfunction.

29 nic heart failure caused by left ventricular systolic dysfunction.

30 k of death in patients with left ventricular systolic dysfunction.

31 ory patients with chronic heart failure with systolic dysfunction.

32 rmed safely in children with ESRD and severe systolic dysfunction.

33 strongest in patients with left ventricular systolic dysfunction.

34 especially in patients with left ventricular systolic dysfunction.

35 ed median time of 8.4 years after developing systolic dysfunction.

36 th abnormal LV geometry but not diastolic or systolic dysfunction.

37 and specific biomarker for the detection of systolic dysfunction.

38 heart failure due to marked left ventricular systolic dysfunction.

39 ventricular dilation that is associated with systolic dysfunction.

40 th moderate to severe heart failure (HF) and systolic dysfunction.

41 al expression correlated with left ventricle systolic dysfunction.

42 and adverse LV remodeling associated with LV systolic dysfunction.

43 ng during infarct maturation associated with systolic dysfunction.

44 ents with heart failure and left ventricular systolic dysfunction.

45 coronary artery disease and left-ventricular systolic dysfunction.

46 associated with left ventricle dilation and systolic dysfunction.

47 be developed as therapeutic agents to treat systolic dysfunction.

48 tolic dysfunction; and pattern 4, dilated RV systolic dysfunction.

49 ents with heart failure and left ventricular systolic dysfunction.

50 evalence of moderate-severe left ventricular systolic dysfunction.

51 homeostasis in an efficient way to minimize systolic dysfunction.

52 ncrease in oxidative stress, hypertrophy and systolic dysfunction.

53 patients with concomitant moderate AS and LV systolic dysfunction.

54 tion defects on the ECG and left ventricular systolic dysfunction.

55 e, atrial fibrillation, and left ventricular systolic dysfunction.

56 jury, hypertrophy, fibrosis, remodeling, and systolic dysfunction.

57 n models examined admission risk factors for systolic dysfunction.

58 tched diet induced obese mice do not display systolic dysfunction.

59 wed by LV diastolic dysfunction (16%) and LV systolic dysfunction (10%).

60 In subgroup analysis, patients with baseline systolic dysfunction (116 patients; mean EF, 44%) showed

61 years) complicated by left ventricular (LV) systolic dysfunction; (2) an age- and sex- matched hyper

62 aits: 1 each with LV internal dimensions and systolic dysfunction, 3 each with LV mass and wall thick

63 In patients with left ventricle systolic dysfunction, 37% (10/27) showed an improvement

64 inhibitor/angiotensin receptor blockers for systolic dysfunction, (4) beta-blockers at discharge, (5

65 onsisted of left ventricular dilation (68%), systolic dysfunction (46%), and myocardial fibrosis (67%

66 on (21.3%), left atrial enlargement (15.3%), systolic dysfunction (6.3%), and ischemia (6.3%).

67 cant improvement in EF only in patients with systolic dysfunction (+7.44%; 95% CI, 5.4-9.5).

68 (LV) diastolic dysfunction, longitudinal LV systolic dysfunction, abnormal ventricular-arterial coup

69 dicted the development of end-stage HCM with systolic dysfunction (adjusted hazard ratio, 1.80/10% in

70 ents with heart failure and left ventricular systolic dysfunction after an acute myocardial infarctio

71 nto the cohort that developed left ventricle systolic dysfunction after catecholamine stress.

72 (p53 (-/-) ) developed left ventricular (LV) systolic dysfunction after doxorubicin treatment.

73 pendently associated with the development of systolic dysfunction after moderate-severe traumatic bra

74 Persistent severe left ventricular (LV) systolic dysfunction after myocardial infarction (MI) is

75 In EPHESUS (Eplerenone in Patients With Systolic Dysfunction After Myocardial Infarction), many

76 c Smad3 knockout) mice exhibited accelerated systolic dysfunction after pressure overload, evidenced

77 art failure and death, and the resolution of systolic dysfunction after successful catheter ablation

78 ric LV wall thickness, LV dilatation, and LV systolic dysfunction after TAC compared with control mic

79 re commonly associated with left ventricular systolic dysfunction, although isolated and early RV dys

80 vascular ischemia and prevention of overt LV systolic dysfunction, although randomized controlled tri

81 dividuals with asymptomatic left ventricular systolic dysfunction (ALVSD), especially in populations

82 pendently associated with the development of systolic dysfunction among moderate-severe traumatic bra

83 evaluate the prevalence of left ventricular systolic dysfunction among patients who experience their

84 infusion, but that Micu2(-/-) mice exhibited systolic dysfunction and 30% lethality from abdominal ao

85 and prevent the development of tumor-induced systolic dysfunction and atrophy.

86 tality in medically treated patients with LV systolic dysfunction and CAD, nor does it identify patie

87 her CABG improved angina in patients with LV systolic dysfunction and CAD.

88 rited cardiomyopathy that is associated with systolic dysfunction and cardiac arrhythmias.

89 ected to 26G TAC additionally exhibited mild systolic dysfunction and cardiac fibrosis, whereas mice

90 ) (P < .001); prevalence of left ventricular systolic dysfunction and chronic kidney disease also inc

91 trial and ventricular remodeling, along with systolic dysfunction and comparable intra-cardiac fibros

92 med any single cytokine in the prediction of systolic dysfunction and death.

93 ped cardiac hypertrophy and left ventricular systolic dysfunction and died prematurely from heart fai

94 lusion In participants with liver cirrhosis, systolic dysfunction and elevated parameters of myocardi

95 ) is a common form of cardiomyopathy causing systolic dysfunction and heart failure.

96 ypertrophy with concentric geometry precedes systolic dysfunction and heart failure.

97 rtrophic response is a major risk factor for systolic dysfunction and heart failure.

98 In post-myocardial infarction with systolic dysfunction and HF, low serum chloride was asso

99 diovascular disease and indexes of global LV systolic dysfunction and hypertrophy (HR: 1.80; 95% CI:

100 ng-term LVEF, reduced incidence of severe LV systolic dysfunction and ICD indications, and fewer hear

101 These changes lead to diastolic and systolic dysfunction and impaired reserve capacity.

102 to an angiotensin II/AT1 receptor-dependent systolic dysfunction and impaired vascular function.

103 he prevalence of overt left ventricular (LV) systolic dysfunction and its associated risk factors hav

104 Left ventricular (LV) systolic dysfunction and moderate aortic stenosis (AS) a

105 ents with heart failure and left ventricular systolic dysfunction and patients with heart failure and

106 al mechanisms pertaining to left ventricular systolic dysfunction and remodeling, systemic inflammati

107 and the greatest degree of left ventricular systolic dysfunction and remodeling.

108 ury, left ventricular fibrosis that precedes systolic dysfunction, and a high incidence of ventricula

109 ed with adverse left ventricular remodeling, systolic dysfunction, and a reduction in survival in the

110 ilation, increased cardiomyocyte cell death, systolic dysfunction, and conduction abnormalities.

111 nificant coronary stenoses, left ventricular systolic dysfunction, and death during follow-up.

112 tion, including arrhythmia, left ventricular systolic dysfunction, and myocardial infarction.

113 pulations, in patients with left ventricular systolic dysfunction, and particularly when substantial

114 nostic impact over and above LV dilation, LV systolic dysfunction, and presence of LGE.

115 D exhibit features of early LV diastolic and systolic dysfunction, and these abnormalities are more s

116 t, markers of LV relaxation, longitudinal LV systolic dysfunction, and ventricular-arterial coupling

117 lic function; pattern 3, normal RV size with systolic dysfunction; and pattern 4, dilated RV systolic

118 alone for the diagnosis of left ventricular systolic dysfunction, aortic or mitral valve disease, or

119 l cardiac function but efficiently prevented systolic dysfunction, apoptosis, and fibrosis, while att

120 Patients with concomitant moderate AS and LV systolic dysfunction are at high risk for clinical event

121 ailure with reduced ejection fraction due to systolic dysfunction are engaging an ever-expanding comp

122 diomyopathy, manifested by LV dilatation and systolic dysfunction, as well as overexpression of genes

123 s after TAC, C-dnO1 mice were protected from systolic dysfunction (assessed by preserved left ventric

124 ts experienced significant right ventricular systolic dysfunction at discharge and 1 month with norma

125 0(+) STEMI patients had an increased risk of systolic dysfunction at discharge and an increased risk

126 ith dilated cardiomyopathy without severe LV systolic dysfunction at high risk of SCD.

127 l fibrosis, and to some extent to myocardial systolic dysfunction attributable to the shift of calciu

128 present with heart failure, left ventricular systolic dysfunction, AV block, atrial or ventricular ar

129 reduce SR Ca available for release, causing systolic dysfunction; (b) elevate diastolic [Ca]i, contr

130 cal data of patients with moderate AS and LV systolic dysfunction between 2010 and 2015 from 4 large

131 For patients with atrioventricular block and systolic dysfunction, biventricular pacing not only redu

132 ction by 2 weeks (20% increase in E/E'), and systolic dysfunction by 3 weeks (16% decrease in % eject

133 e investigated whether left ventricular (LV) systolic dysfunction by global longitudinal strain (GLS)

134 LV systolic dysfunction by GLS was a powerful and independe

135 disruption significantly exacerbated post-IR systolic dysfunction (by ultrasound echocardiography) an

136 ical Rate Control in Atrial Fibrillation and Systolic Dysfunction [CAMERA-MRI]; ACTRN12613000880741).

137 Early systolic dysfunction can occur in previously healthy pat

138 rt damage, characterized by left-ventricular systolic dysfunction, cardiac hypertrophy and myocardial

139 ar regurgitation, and less right ventricular systolic dysfunction compared with SAVR.

140 Patients with left ventricular (LV) systolic dysfunction, coronary artery disease (CAD), and

141 ype, family history of CM (DCM), severity of systolic dysfunction (DCM), and extent of LV hypertrophy

142 valve area between 1.0 and 1.5 cm(2) and LV systolic dysfunction defined as LV ejection fraction <50

143 In these patients, LV systolic dysfunction, defined in the guidelines as eject

144 This dynamic systolic dysfunction, demonstrated on the Doppler curves

145 Left ventricular systolic dysfunction determined by reduced strain-rate s

146 diography in patients with various levels of systolic dysfunction, diastolic abnormalities, and valvu

147 rative care reduced the combined rates of LV systolic dysfunction, diastolic dysfunction, and heart f

148 dial ischemia, left ventricular hypertrophy, systolic dysfunction, diastolic dysfunction, or left atr

149 The degree of left ventricular (LV) systolic dysfunction did not correlate with the quantity

150 , focusing on patients with left ventricular systolic dysfunction, either nonischemic or ischemic.

151 tivessel disease and severe left ventricular systolic dysfunction (ejection fraction </=35%) who unde

152 ociated with overt left or right ventricular systolic dysfunction (ejection fraction <50%).

153 Graft dysfunction was defined as significant systolic dysfunction (ejection fraction [EF] <45%) or th

154 om 2004 to 2017, were identified with ES and systolic dysfunction (ejection fraction [EF] <50%), foll

155 c cardiomyopathy and severe left ventricular systolic dysfunction (ejection fraction</=35%).

156 152+/-0.019 in atg7 cKO; P<0.05) and induced systolic dysfunction (end systolic pressure-volume relat

157 (-/-) mice developed cardiac hypertrophy and systolic dysfunction, evidenced by a 5-fold greater hear

158 with survivors, nonsurvivors showed worse RV systolic dysfunction (FAC=36.5+/-12.7% versus 33.9+/-11.

159 tric hypertrophy preceded the development of systolic dysfunction, fetal gene activation, fibrosis, a

160 In patients with severe systolic dysfunction following acute MI with an EF </=35

161 important, particularly among patients with systolic dysfunction, for whom most HF-specific therapie

162 nfection, hypokalaemia, and left ventricular systolic dysfunction (four [<1%] each).

163 Patients with systolic dysfunction frequently demonstrate multiple pat

164 dy demonstrates that in rats with MI induced systolic dysfunction, GGF2 treatment improves cardiac fu

165 echocardiography documented left ventricular systolic dysfunction had a central venous oxygen saturat

166 ator of HFpEF, the prevalence of concomitant systolic dysfunction has not been clearly defined.

167 cal coupling, a well-described phenomenon in systolic dysfunction, has not been well studied in diast

168 h significant secondary TR, patients with RV systolic dysfunction have worse clinical outcome regardl

169 HF risk factors, antecedent left ventricular systolic dysfunction (hazard ratio, 2.33; 95% confidence

170 uced all-cause mortality in patients with RV systolic dysfunction, hazards ratio 0.41 (95% CI, 0.17-0

171 0.97), P=0.04 but not in patients without RV systolic dysfunction, hazards ratio 1.87 (95% CI, 0.85-3

172 I]: 1.20 to 1.83) and right ventricular (RV) systolic dysfunction (HR: 1.68; CI: 1.35 to 2.07).

173 Moreover, these mice were protected from systolic dysfunction, hypertrophy, lung congestion, and

174 Systolic dysfunction in Akita/ACE2KO mice was linked to

175 dysfunction in wild-type mice, and profound systolic dysfunction in mice lacking cardiac PGC-1alpha.

176 erses preestablished cardiac hypertrophy and systolic dysfunction in mice subjected to transverse aor

177 g (EAM) in identifying irreversibility of LV systolic dysfunction in patients with left ventricular n

178 dinal course, and admission risk factors for systolic dysfunction in patients with moderate-severe tr

179 tcomes of asymptomatic left ventricular (LV) systolic dysfunction in patients with severe aortic sten

180 The presence of severe systolic dysfunction in pediatric dialysis patients shou

181 Accelerated systolic dysfunction in pressure-overloaded FS3KO mice w

182 ation of an MMP-8 inhibitor attenuated early systolic dysfunction in pressure-overloaded FS3KO mice,

183 s, p47(phox)KO mice showed markedly worsened systolic dysfunction in response to pressure overload at

184 eveloping cardiac hypertrophy, fibrosis, and systolic dysfunction in response to transverse aortic co

185 ntricular [LV] outflow obstruction or due to systolic dysfunction in the absence of obstruction; or a

186 is an important component of diastolic, and systolic, dysfunction in heart failure (HF) and depends

187 In this large cohort of patients with LV systolic dysfunction, in whom FMR and LV characteristics

188 ebo group had cardiac hypertrophy, fibrosis, systolic dysfunction, increased oxidized to total glutat

189 as common in our HD study population, and RV systolic dysfunction independently predicted mortality.

190 severe AS, the prevalence of asymptomatic LV systolic dysfunction is 0.4%.

191 safety among patients with left ventricular systolic dysfunction is based on small populations, and

192 an twice as high as in control subjects, and systolic dysfunction is equally reduced in SCM and LAD M

193 phy and diastolic dysfunction; a subclinical systolic dysfunction is evident only in PA.

194 In chronic Chagas disease, RV systolic dysfunction is more commonly associated with le

195 new-onset heart failure or left ventricular systolic dysfunction is more strongly associated with fu

196 is preserved in RA patients, indicating that systolic dysfunction is not an intrinsic feature of RA.

197 a decrease in diastolic function followed by systolic dysfunction later in life.

198 l infarction complicated by left ventricular systolic dysfunction (left ventricular ejection fraction

199 rved in the term-born adults and 6% had mild systolic dysfunction (<45%).

200 rmal myocardial relaxation and diastolic and systolic dysfunction (LV ejection fraction) the internal

201 e of AVB, AA, sustained VA, left ventricular systolic dysfunction (LVD) (= left ventricular ejection

202 Patients with systolic dysfunction (LVEF <or= 0.40) had significantly

203 Among patients with left ventricular systolic dysfunction (LVSD) (n = 3,001), beta-blockers w

204 Left ventricular systolic dysfunction (LVSD) accounts for almost 25% of n

205 k factor for development of left ventricular systolic dysfunction (LVSD) and can complicate LVSD mana

206 not differentiated between left ventricular systolic dysfunction (LVSD) and HF with preserved ejecti

207 raphy examination to define left ventricular systolic dysfunction (LVSD) and left ventricular diastol

208 ata, including grade 3 to 4 left ventricular systolic dysfunction (LVSD) and significant asymptomatic

209 t failure (HF) secondary to left ventricular systolic dysfunction (LVSD) are frequently deficient in

210 ld if there was evidence of left ventricular systolic dysfunction (LVSD) defined as SF < 28% or EF <

211 trial fibrillation (AF) and left ventricular systolic dysfunction (LVSD) frequently co-exist despite

212 Some patients with left ventricular systolic dysfunction (LVSD) have a dramatic improvement

213 ciated with the severity of left ventricular systolic dysfunction (LVSD) in patients with chronic Cha

214 revent chemotherapy-induced left ventricular systolic dysfunction (LVSD) in patients with hematologic

215 d by heart failure (HF) and left ventricular systolic dysfunction (LVSD) in the Apixaban for Reductio

216 entricular failure (RVF) in left ventricular systolic dysfunction (LVSD) is associated with high morb

217 c cardiomyopathy (HCM) with left ventricular systolic dysfunction (LVSD), defined as occurring when l

218 examined the prevalence of left ventricular systolic dysfunction (LVSD), diastolic dysfunction (DD),

219 determine the prevalence of left ventricular systolic dysfunction (LVSD), including symptomatic (ie,

220 In patients with left ventricular systolic dysfunction (LVSD), the rate at which oxygen up

221 e men, and 1791 (40.2%) had left ventricular systolic dysfunction (LVSD).

222 ents with AMI without HF or left ventricular systolic dysfunction (LVSD).

223 nting with dyspnea who have left ventricular systolic dysfunction (LVSD).

224 rs (372 [69%] with baseline left ventricular systolic dysfunction [LVSD]).

225 he study patients developed left ventricular systolic dysfunction (mean [SD] ejection fraction, 25% [

226 y ECG or echocardiography], left ventricular systolic dysfunction, microalbuminuria, and a reduced an

227 enrolling 2,331 ambulatory HF patients with systolic dysfunction (New York Heart Association functio

228 AT1 receptor blocker, irbesartan rescued the systolic dysfunction, normalized altered signaling pathw

229 In patients with HF due to LV systolic dysfunction, NT-proBNP-guided therapy was super

230 d tissue angiotensin II levels, resulting in systolic dysfunction on a background of impaired diastol

231 efined as grade 2 or higher left ventricular systolic dysfunction on the basis of Common Terminology

232 had diastolic dysfunction in the absence of systolic dysfunction or cardiac hypertrophy.

233 y and not a surrogate for the severity of LV systolic dysfunction or FMR.

234 vs. 5%; p = 0.013); 3) higher prevalence of systolic dysfunction or restrictive LV filling at last e

235 the absence of significant left ventricular systolic dysfunction or valve disease, due to impaired v

236 unacceptable angina, severe left ventricular systolic dysfunction, or high-risk coronary anatomy.

237 To assess the effect of CRT in less severe systolic dysfunction, outcomes in the REsynchronization

238 n patients with and without heart failure or systolic dysfunction ( P interaction =0.30).

239 NCCM with DCM (53%) was associated with LV systolic dysfunction (p < 0.001), increased risk for maj

240 reach class I indications of symptoms or LV systolic dysfunction, particularly in patients with dege

241 tivessel disease and severe left ventricular systolic dysfunction, PCI with everolimus-eluting stent

242 up) and one new symptomatic left ventricular systolic dysfunction (post-crossover) occurred since the

243 ading cause of death (10 of 17; 59%), and LV systolic dysfunction predicted an adverse outcome.

244 onduction abnormalities and left ventricular systolic dysfunction predisposing to heart failure.

245 white matter hyperintensities, with cardiac systolic dysfunction present in the two oldest patients.

246 e expansion (VE) in humans with pre-clinical systolic dysfunction (PSD) and pre-clinical diastolic dy

247 igher death risk included LVEF </=45% and RV systolic dysfunction rather than neither (HR: 2.04; CI:

248 th stable heart failure and left ventricular systolic dysfunction receiving guideline-indicated treat

249 All patients with early systolic dysfunction recovered in 1 week.

250 , heart failure, and severe left ventricular systolic dysfunction remains unclear.

251 l mice and demonstrated chamber dilation and systolic dysfunction resembling human dilated cardiomyop

252 Left ventricular diastolic or systolic dysfunction results in increased preload and af

253 nical significance of right ventricular (RV) systolic dysfunction (RVD) in patients with heart failur

254 ostic significance of right ventricular (RV) systolic dysfunction (RVSD).

255 ventricular diastolic and right ventricular systolic dysfunction seem to explain the association of

256 cancer cachexia-induced cardiac atrophy and systolic dysfunction, suggesting therapies that may help

257 lization in this well-treated HF cohort with systolic dysfunction, supporting recommendations that ti

258 in patients in sinus rhythm with significant systolic dysfunction, symptomatic heart failure, and pro

259 Hypertension, obesity, and systolic dysfunction that are present before a person is

260 re overload leads to dilative remodeling and systolic dysfunction that may be mediated by changes in

261 ion in cardiomyocytes, mice developed severe systolic dysfunction that resulted in death within 8 day

262 the rates of hypertension, left ventricular systolic dysfunction, the hand-foot syndrome, and mucosi

263 groups, with no increase in left ventricular systolic dysfunction; the rates of febrile neutropenia a

264 14 patients (38%) presented left ventricular systolic dysfunction; there were significant association

265 me of AFCA in patients with left ventricular systolic dysfunction, to evaluate predictors of recurren

266 V dilation (tricuspid annulus>=40 mm) and RV systolic dysfunction (tricuspid annulus systolic excursi

267 ies including patients with left ventricular systolic dysfunction undergoing AFCA were included.

268 mmunity-based patients with left ventricular systolic dysfunction undergoing primary prevention ICD i

269 Six children with ESRD and severe systolic dysfunction underwent renal transplantation.

270 Five hundred eight patients with CHF due to systolic dysfunction underwent resting cardiovascular me

271 eased vasopressor support (right ventricular systolic dysfunction, unremarkable transesophageal echoc

272 of future arrhythmic events in patients with systolic dysfunction using the gold standard of cardiova

273 in patients with chronic heart failure with systolic dysfunction, using patient data that are routin

274 ery ligation which, 8-10 weeks later, led to systolic dysfunction (verified echocardiographically) an

275 ssessed by transthoracic echocardiogram, and systolic dysfunction was defined as fractional shortenin

276 RV systolic dysfunction was defined as reduced RV ejection

277 RV systolic dysfunction was defined as RVEF <=45%.

278 Subclinical left ventricular (LV) systolic dysfunction was defined using values of absolut

279 t ventricular ejection fraction, isolated RV systolic dysfunction was found in 7 (4.4%) patients, 2 o

280 osis was present in 55 patients (72%) and LV systolic dysfunction was identified in 13 patients (24%)

281 RV systolic dysfunction was identified in 58 (37%) individu

282 ein thrombosis, is more common, but acute LV systolic dysfunction was noted in ~20%.

283 At diagnosis, LV systolic dysfunction was present in 20% of subjects and

284 Median RVEF was 51%, RV systolic dysfunction was present in 75 (31%) patients, a

285 LV systolic dysfunction was reported in 40% of men (who had

286 Heart failure because of systolic dysfunction was the most common clinical presen

287 art failure attributable to left ventricular systolic dysfunction were examined in this post hoc anal

288 mptomatic heart failure and left ventricular systolic dysfunction were randomized to either 24 weeks

289 ubjects with HF due to left ventricular (LV) systolic dysfunction were randomized to receive either s

290 specific (86.1%) biomarker for detecting LV systolic dysfunction, which was comparable to BNP(1-32),

291 concentric LV remodeling with diastolic and systolic dysfunction, which was prevented by both HIT an

292 nd cisplatin), and one from left ventricular systolic dysfunction, which was probably related to MAPI

293 etic registries with HF and left ventricular systolic dysfunction who were discharged on beta-blocker

294 on was used to verify the relationship of RV systolic dysfunction with age, sex, functional class, us

295 with dengue in the form of left ventricular systolic dysfunction with increased left myocardial perf

296 holds and identification of left ventricular systolic dysfunction with LVEF of 40% or less as measure

297 atrioventricular block and left ventricular systolic dysfunction with NYHA class I, II, or III heart

298 tress, which also increased, resulting in LV systolic dysfunction with reductions in ejection fractio

299 R46 SNP was significantly associated with LV systolic dysfunction, with each minor allele additively

300 0%) mild traumatic brain injury patients had systolic dysfunction within the first day after injury (